Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Common Equity (2023 - 2025)

Beta Bionics (BBNX) has disclosed Common Equity for 3 consecutive years, with $287.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 217.22% to $287.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287.6 million through Dec 2025, up 217.22% year-over-year, with the annual reading at $287.6 million for FY2025, 217.22% up from the prior year.
  • Common Equity hit $287.6 million in Q4 2025 for Beta Bionics, down from $294.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $313.8 million in Q1 2025 to a low of -$245.4 million in Q4 2024.
  • Historically, Common Equity has averaged $9.4 million across 3 years, with a median of -$203.1 million in 2023.
  • Biggest five-year swings in Common Equity: fell 20.8% in 2024 and later soared 246.39% in 2025.
  • Year by year, Common Equity stood at -$203.1 million in 2023, then decreased by 20.8% to -$245.4 million in 2024, then skyrocketed by 217.22% to $287.6 million in 2025.
  • Business Quant data shows Common Equity for BBNX at $287.6 million in Q4 2025, $294.8 million in Q3 2025, and $301.6 million in Q2 2025.